Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice

Biomedicine and Pharmacotherapy

Volumn 64, Issue 7, 2010, Pages 441-445

  Luo, Junyong ^a   Cao, Jichao ^a   Jiang, Xueliang ^b   Cui, Huifei ^a  

^a SHANDONG UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Low molecular weight heparin; Rectal suppository; Ulcerative colitis

Indexed keywords

ACETIC ACID; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; MUSASHI 1 PROTEIN; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SUPPOSITORY; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLITIS, ULCERATIVE; COLON; CYTOKINES; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; INTERLEUKIN-6; MALE; MICE; PEROXIDASE; POLYETHYLENE GLYCOLS; SUPPOSITORIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956425872     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.01.013     Document Type: Article

References (29)

1. Xia B., Han H., Zhang K.J., Li J., Guo G.S., Gong L.L., et al. Effects of low molecular weight heparin on platelet surface P-selectin expression and serum interleukin-8 production in rats with trinitrobenzene sulphonic acid-induced colitis. World J Gastroenterol 2004, 10:729-732.
2. Wan M.X., Liu Q., Wang Y., Thorlacius H. Protective effect of low molecular weight heparin on experimental colitis: Role of neutrophil recruitment and TNF-α production. Inflamm Res 2002, 51:182-187.
3. Celasco G, Moro L., Bozzella R., Mangano K., Quattrocchi C., Aiello C., et al. Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci 2008, 53:3170-3175.
4. Cahalon L., Lider O., Schor H., Avron A., Gilat D., Hershkoviz R., et al. Heparin disaccharides inhibit tumor necrosis factor-a production by macrophages and arrest immune inflammation in rodents. Int Immunol 1997, 9:1517-1522.
5. Torkvist L., Thorlacius H., Sjoqvist U., Bohmanl, Lapidus A., Flood L., et al. Low molecular weight heparin as adjuvant therapy inactive ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1323-1328.
6. Folwaczny C., Wiebecke B., Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999, 94:1551-1555.
7. Evans R.C., Wong V.S., Morris A.I., Rhodes J.M. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther 1997, 11:1037-1040.
8. Ang Y.S., Mahmud N., White B., Byrne M., Kelly A., Lawler M., et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:1015-1022.
9. Dotan I., Hallak A., Arber N., Santo M., Alexandrowitz A., Knaani Y., et al. Lowdose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: An open trial. Dig Dis Sci 2001, 46:2239-2244.
10. Cui H.F., Jiang X.L. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J Gastroenterol 1999, 5:448-450.
11. Pellequer Y., Meissner Y., Ubrich N., Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007, 321:726-733.
12. Fitzpatrick L.R., Wang J., Le M. In vitro and in vivo effects of gliotoxin, a fungal metabolite: Efficacy against dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 2000, 45:2327-2336.
13. Maines L.W., Fitzpatrick L.R., French K.J., Zhuang Y., Xia Z., Keller S.N., et al. Suppression of ulcerative colitis in mice by orally-available inhibitors of sphingosine kinase. Dig Dis Sci 2008, 53:997-1012.
14. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase. Gastroenterology 1984, 87:1344-1350.
15. Deventer S.J.H. Tumor necrosis factor and Crohn's disease. Gut 1997, 40:443-448.
16. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-SanRoman A., Taxonera C., Casis B., Tabernero S., et al. Open-label infliximab therapy in ulcerative colitis: A multicenter survey of results and predictors of response. Hepatogastroenterology 2008, 55:1609-1614.
17. Hyams J.S., Lerer T., Griffiths A., Pfefferkorn M., Kugathasan S., Evans J., et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15:816-822.
18. Weiss S.J. Tissue destruction by neutrophils. N Engl J Med 1989, 320:365-376.
19. Polgar A., Brozik M., Toth S., Holub M., Hegyi K., Kadar A., et al. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis. Med Sci Monit 2000, 6:13-18.
20. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
21. Herbert J.M., Bono F., Herault J.P., Avril C., Dol F., Mares A.M., et al. Effect or protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. Clin Investig 1998, 101:993-1000.
22. Papapetropoulos A., Piccardi P., Cirino G., Bucci M., Sorrentino R., Cicala C., et al. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A 1998, 95:4738-4742.
23. Joo S.S., Won T.J., Kim J.S., Yoo Y.M., Tak E.S., Park S.Y., et al. Inhibition of coagulation activation and inflammation by a novel factor Xa inhibitor synthesized from the Earthworm Eisenia andrei. Biol Pharm Bull 2009, 32:253-258.
24. Saifeddine M., Al-Ani B., Cheng C.H., Wang L., Hollenberg M.D. Rat proteinase activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol 1996, 118:521-530.
25. Okano H., Kawahara H., Toriya M., Nakao K., Shibata S., Imai T. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res 2005, 306:349-356.
26. Potten C.S., Booth C., Tudmor G.L., Booth D., Brady G., Hurley P., et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation 2003, 71:28-41.
27. Kayahara T., Sawada M., Takaishi S., Fukui H., Seno H., Fukuzawa H., et al. Chiba T Candidate markers for stem and early progenitor cells Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine. FEBS Lett 2003, 535:131-135.
28. Sakatani T., Kaneda A., Iacobuzio-Donahue C.A., Carter M.G., de Boom Witzel S., Okano H., et al. Loss of imprinting of Igf2 alter intestinal maturation and tumorigenesis in mice. Science 2005, 307:1976-1978.
29. Murata H., Tsuji S., Tsujii M., Nakamura T., Fu H.Y., Eguchi H., et al. Helicobacter Pylori infection induces candidate stem cell marker Musashi-1 in the human gastric epithelium. Dig Dis Sci 2008, 53:363-369.